90 studies found for:    Obinutuzumab
Show Display Options
Rank Status Study
1 Completed
Has Results
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Chlorambucil
2 Completed
Has Results
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Condition: Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Intervention: Drug: Obinutuzumab
3 Active, not recruiting Single and Multiple-dose Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
Condition: Kidney Failure, Chronic
Intervention: Drug: Obinutuzumab
4 Not yet recruiting Lenalidomide and Obinutuzumab for Previously Untreated CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab
5 Active, not recruiting TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: TGR-1202 + Obinutuzumab + Chlorambucil
6 Recruiting Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Condition: Leukemia
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab
7 Recruiting Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Lenalidomide
8 Recruiting Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: GA101;   Drug: ibrutinib
9 Recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: obinutuzumab
10 Recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib
11 Not yet recruiting A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Graft vs. Host Disease
Interventions: Drug: Obinutuzumab;   Drug: Placebo
12 Completed
Has Results
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)
Condition: Lymphocytic Leukemia, Chronic
Intervention: Drug: Obinutuzumab
13 Recruiting A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an Antibody Targeting Certain Types of Immune Cells, in Participants With Lupus Nephritis (LN)
Condition: Lupus Nephritis
Interventions: Drug: Mycophenolate Mofetil;   Drug: Obinutuzumab;   Drug: Placebo
14 Not yet recruiting Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Venetoclax
15 Not yet recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
16 Completed
Has Results
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
Condition: Lymphoma
Intervention: Drug: Obinutuzumab
17 Completed
Has Results
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: obinutuzumab (RO5072759);   Drug: rituximab
18 Terminated Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Conditions: Lymphocytic Leukemia, Chronic;   Lymphoma, Small Lymphocytic
Interventions: Drug: IPI-145 (duvelisib);   Drug: Obinutuzumab
19 Recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
20 Recruiting A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.